Endocrine Society Experts Issue Clinical Practice Guideline on Hypopituitarism October 13, 2016 | Guideline calls for hormone replacement therapy to restore hormones to healthy levels. The Endocrine Society today issued a Clinical Practice Guideline that recommends treating insufficient hormone levels in individuals with hypopituitarism by replacing hormones at levels as close to the body’s natural patterns as possible. The guideline, titled “Hormonal Replacement…
CEU Session | No credit available
Roberto R. Salvatori, MD
Follow a discussion on causes, treatment, and what patients can expect over time in cases of hypopituitarism with an emphasis on the Society’s recent practice guidelines.
Challenging Cases in the Management of Acromegaly
ENDO Session | No credit available
John A. H. Wass, MD; Mônica R. Gadelha, MD, PhD; and Mark E. Molitch, MD
Learn how to tackle challenging cases with difficult to interpret results with diagnosing and treating acromegaly.
Selecting a Target in Refractory Cushing Disease
ENDO Session | No credit available
Maria Fleseriu, MD
What’s your best option? Use the latest information on medical therapies from clinical trials to treat your patients with persistent disease.
Endocrine Fellows Series: Pituitary Disorders Conference 2016
Fellows Workshop Webcast | 14.0 AMA PRA Category 1 Credits™
Program Directors: Anne Klibanski, MD and Janet Schlechte, MD
Engage in a comprehensive program of current topics for pediatric and adult endocrine fellows including imaging, treatment modalities, practice management strategies, and practical approaches to challenging cases.
Endocrine Facts & Figures: Hypothalamic-Pituitary
Research Resource | No credit available
Advisory Panel Chair: Robert A. Vigersky, MD
Updated epidemiological data and in-depth discussion on pituitary dysfunction, pituitary adenomas, and other sellar lesions with current citations and expert insights.
Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment JCEM | July 28, 2016 Jakob Dal, Katrine Lundby Høyer, Steen Bønløkke Pedersen, Nils Erik Magnusson, Peter Bjerring, Jan Frystyk, Niels Møller, Niels Jessen and Jens Otto Lunde Jørgensen
Context: Somatostatin analogs (SAs) used in acromegaly to suppress GH secretion and tumor growth also suppress insulin secretion and may impact GH signaling. Objective: To compare GH and insulin signaling after iv GH exposure in acromegalic patients controlled by surgery (n = 9) or SA (n = 9). Design: Each…
Dopamine Agonists Can Reduce Cystic Prolactinomas JCEM | July 26, 2016 Alexander Faje, Paweena Chunharojrith, Joshipura Nency, Beverly M. K. Biller, Brooke Swearingen and Anne Klibanski
Context: Cystic prolactinomas are considered resistant to volume reduction by dopamine agonists (DAs). Although several individual case reports and small case series have suggested that DAs may reduce these lesions, larger series using standardized imaging metrics are lacking. Objective: The objectives of the study were to assess the efficacy of DAs…
Hormonal Replacement in Hypopituitarism in Adults JCEM | October 13, 2016 Maria Fleseriu (chair), Ibrahim A. Hashim, Niki Karavitaki, Shlomo Melmed, M. Hassan Murad, Roberto Salvatori, and Mary H. Samuels
Using an evidence-based approach, this guideline addresses important clinical issues regarding the evaluation and management of hypopituitarism in adults, including appropriate biochemical assessments, specific therapeutic decisions…
Acromegaly JCEM | October 30, 2014 Laurence Katznelson, Edward R. Laws Jr, Shlomo Melmed, Mark E. Molitch, Mohammad Hassan Murad, Andrea Utz, and John A. H. Wass
Using an evidence-based approach, this acromegaly guideline addresses important clinical issues regarding the evaluation and management of acromegaly, including the appropriate biochemical assessment, a therapeutic algorithm…
Treatment of Cushing's Syndrome JCEM | July 29, 2015 Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, M. Hassan Murad, John Newell-Price, Martin O. Savage, and Antoine Tabarin
Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes…
Diagnosis and Treatment of Hyperprolactinemia JCEM | July 2, 2013 Shlomo Melmed, Felipe F. Casanueva, Andrew R. Hoffman, David L. Kleinberg, Victor M. Montori, Janet A. Schlechte, and John A. H. Wass
Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced…
Evaluation and Treatment of Adult Growth Hormone Deficiency JCEM | July 2, 2013 Mark E. Molitch, David R. Clemmons, Saul Malozowski, George R. Merriam, and Mary Lee Vance
Growth Hormone Deficiency (GHD) can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural…
Pituitary Incidentaloma JCEM | July 2, 2013 Pamela U. Freda, Albert M. Beckers, Laurence Katznelson, Mark E. Molitch, Victor M. Montori, Kalmon D. Post, and Mary Lee Vance
We recommend that patients with a pituitary incidentaloma undergo a complete history and physical examination, laboratory evaluations screening for hormone hypersecretion and for hypopituitarism, and…
The Diagnosis of Cushing's Syndrome JCEM | January 14, 2009 Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, John Newell-Price, Martin O. Savage, Paul M. Stewart, and Victor M. Montori
After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with…